Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fresenius Medical Care AG (FMCQF) EBITDA (2016 - 2025)

Historic EBITDA for Fresenius Medical Care AG (FMCQF) over the last 17 years, with Q3 2025 value amounting to $557.1 million.

  • Fresenius Medical Care AG's EBITDA fell 3873.92% to $557.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year decrease of 1452.49%. This contributed to the annual value of $3.6 billion for FY2024, which is 106.34% down from last year.
  • As of Q3 2025, Fresenius Medical Care AG's EBITDA stood at $557.1 million, which was down 3873.92% from $906.7 million recorded in Q2 2025.
  • Fresenius Medical Care AG's EBITDA's 5-year high stood at $1.1 billion during Q3 2021, with a 5-year trough of $557.1 million in Q3 2025.
  • Over the past 5 years, Fresenius Medical Care AG's median EBITDA value was $864.1 million (recorded in 2022), while the average stood at $875.3 million.
  • In the last 5 years, Fresenius Medical Care AG's EBITDA soared by 975.61% in 2024 and then crashed by 3873.92% in 2025.
  • Fresenius Medical Care AG's EBITDA (Quarter) stood at $1.0 billion in 2021, then decreased by 14.74% to $864.1 million in 2022, then grew by 6.33% to $918.9 million in 2023, then fell by 14.41% to $786.5 million in 2024, then dropped by 29.17% to $557.1 million in 2025.
  • Its EBITDA was $557.1 million in Q3 2025, compared to $906.7 million in Q2 2025 and $763.7 million in Q1 2025.